Topic summary

Second pass at: Reading a combination trial: attributing effect to components

Compounds › Cagrilintide & amylin analogues cagrilintide randomised trial amylin analogues effect size cagrisema

This is a generated summary. It shows the 6 most-liked posts from a topic of 44, in their original order, with the accepted answer included where one exists. It is a reading aid and it will miss nuance — the full topic is the record.

e.lokkenTL2 Moderator23 Mar 2025#1

Second pass at: Reading a combination trial: attributing effect to components — setting out what I have, and where I think it stops being reliable.

I have seen SURMOUNT-2 (Lancet, 2023) cited in support of a claim I do not think it supports, twice this month, so I would like to work through what it actually shows.

My reading is that the trial is sound for its own question and is being stretched to answer a different one. I might be wrong about that, which is why this is a topic rather than a correction.

What I would like from this discussion: someone who disagrees with me to say why, with the section of the paper they are relying on.

24 likes 16mo

h.friskTL2 Moderator7 May 2025#13

post #12 is right about the mechanism and I think understates the practical bit.

Reading the phase 2 paper: it establishes tolerability and efficacy in a selected population on a defined dose escalation. It does not establish the lowest effective dose or the durability over years.

26 likes 15mo

k.dahlbergTL2 Moderator28 May 2025#21

n.boateng, post #11: I disagree with the reply above, and I think the disagreement is substantive rather than terminological. The distinction being drawn does not survive when you look at the published data for this specific question. I would be glad to be shown wrong on this, because the version I am arguing against is more convenient. Go to post

The CagriSema phase 2 paper: a fixed combination of the two components in one weekly injection. The trade-off of a fixed combination is that you cannot titrate the components independently and you cannot attribute effect to one component from a combination trial.

28 likes in reply to #11 14mo

b.demirTL2 Moderator8 Jun 2025#25

Amylin signalling is distinct from GLP-1 signalling. Amylin slows gastric emptying and promotes satiety through a different receptor and different neural pathways. The hypothesis behind combination is two complementary satiety mechanisms with one injection.

21 likes in reply to #11 14mo

ambient_reviewTL3Regular6 Jul 2025 · edited#37

Historical amylin analogues: pramlintide was the only long-acting amylin analogue licensed for some time and its poor adherence was a known limitation. A weekly formulation addresses that practical barrier.

24 likes 13mo

r.jhannsdttirTL3Regular19 Jul 2025#43

26 likes 12mo

Read the full topic (44 posts)

This topic was referenced in

[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretinsCompounds › Cagrilintide & amylin analogues · 25 replies

Promoted into the documentation commons. The content of this topic is maintained at Cagrilintide — reference, with named maintainers and a review date. The promotion was discussed in doc review. Corrections are best raised against the document, which is the version that gets kept current.

Suggested topics

Topic	Participants	Replies	Views	Activity
Historical amylin analogues and what happened to them Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide cagrisema effect size Posting this under the heading it deserves: Historical amylin analogues and what happened to them Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in support of a…	+29	36	31k	1d
The CagriSema phase 2 paper and what a fixed combination buys Compounds › Cagrilintide & amylin analogues randomised trial cagrilintide effect size Posting this under the heading it deserves: The CagriSema phase 2 paper and what a fixed combination buys Everything below is what sits behind that. I have seen SURPASS-2 ( N Engl J Med , 2021) cited in…	+88	93	29k	11mo
Follow-up: Is "synergy" the right word for the combination data? Compounds › Cagrilintide & amylin analogues cagrilintide cagrisema amylin analogues effect size Solved Under review Is "synergy" the right word for the combination data? I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SURPASS-4 ( Lancet , 2021) cited in support of a…		2	41k	14mo
Follow-up: What is genuinely unknown about long-term amylin agonism Compounds › Cagrilintide & amylin analogues effect size amylin analogues cagrisema What is genuinely unknown about long-term amylin agonism I have a specific reason for asking rather than idle curiosity, and the context is below. I have seen SUSTAIN 6 ( N Engl J Med , 2016) cited in support…		2	25k	11mo
[2026 update] Amylin and gastric emptying: overlapping mechanisms with incretins Compounds › Cagrilintide & amylin analogues amylin analogues randomised trial effect size cagrisema Amylin and gastric emptying: overlapping mechanisms with incretins — setting out what I have, and where I think it stops being reliable. Session topic: FLOW ( N Engl J Med , 2024). Please read it before…	+21	25	44k	5mo

Related topics — sharing the tags cagrilintide, randomised trial, amylin analogues

Topic	Participants	Replies	Views	Activity
Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Compounds › Oral incretins orforglipron SOUL trial PIONEER programme randomised trial Solved Asking directly, because I could not find a straight answer: Why fasting instructions for oral semaglutide are not optional advice — does this still hold? Session topic: PIONEER 6 ( N Engl J Med , 2019).…	+98	106	3.1k	10mo
Sample size calculations, read backwards from the published number Evidence › Trials intention to treat surrogate endpoints randomised trial Sample size calculations, read backwards from the published number Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SUSTAIN 6 ( N Engl J Med , 2016). Please…		2	8.1k	6mo
[2026 update] Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA Compounds › Tirzepatide tirzepatide effect size randomised trial Tirzepatide in obstructive sleep apnoea: reading SURMOUNT-OSA — setting out what I have, and where I think it stops being reliable. I have seen STEP 4 ( JAMA , 2021) cited in support of a claim I do not think…		2	58k	11mo
A structured critique template this community uses — a second dataset Evidence › Study critique observational data effect size confounding Solved On the subject in the title: A structured critique template this community uses — a second dataset Working notes rather than a conclusion. Session topic: SELECT ( N Engl J Med , 2023). Please read it before…	+47	51	16k	15h
Second pass at: Designing a personal experiment that could change your mind Research Methods › N-of-1 designs worked example effect size confounding data table Solved Second pass at: Designing a personal experiment that could change your mind Writing it up because I had to work it out twice and would rather nobody else did. Session topic: SURPASS-4 ( Lancet , 2021). Please…	+39	44	632	14mo